What happened

Shares of Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH), a clinical-stage biotech developing antibiotics, continued its impressive climb with another gain of about 15.8%, as of 11:46 a.m. EST on Friday. Following the company's fourth-quarter earnings report on Wednesday, Wall Street analysts continue to raise their price targets for the stock. 

So what

Tetraphase doesn't have any products to sell yet, but investors are more confident that this could change following the company's fourth-quarter and full-year earnings report. Earlier this week, Tetraphase highlighted its progress with its lead antibiotic candidate, intravenous eravacycline for the treatment of complicated intra-abdominal infection (cIAI).

Person running up arrows sloping upward

Image source: Getty Images.

In November, the company released data showing eravacycline was as good, or better, at fighting off infection as carbapenem, a class of antibiotics generally used to treat hospitalized patients with infections caused by bacteria resistant to multiple drugs. The company is running a similar trial pitting its candidate against meropenem, another commonly used antibiotic used to treat cIAI, and expects to announce the results in the fourth quarter this year.

Now what

Another win in the ongoing head-to-head trial against meropenem should be able to support applications to regulatory bodies in the U.S. and the European Union. Hospitals are clamoring for fresh options to treat life-threatening bacterial infections that are increasingly resistant to available antibiotics.

Longtime Tetraphase shareholders can still feel the sting of a market thrashing in 2015 after an oral version of eravacycline flopped in a late-stage trial. Despite somewhat lower demand for the less convenient intravenous version, the antibiotic could go on to generate perhaps $200 million in annual sales. With a market cap of about $260 million, this high-flying biotech stock might have plenty more room to run.

Cory Renauer has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.